• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory protein.
【24h】

Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory protein.

机译：通过体内施用可溶性共刺激蛋白B7.2Ig增强免疫反应。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The identification of both class I- and class II-restricted tumor-associated peptides recognized by T cells has led to the test of these peptides as immunogens in experimental immunotherapy for cancer patients. However, optimal T cell activation requires signaling both through the T cell receptor for antigen and through costimulatory pathways. B7.1 and B7.2 are powerful costimulatory molecules expressed on the surface of antigen-presenting cells. Using a mouse model, we have sought to optimize costimulatory signals during antipeptide responses by administering a soluble form of B7.2 at the time of peptide immunization. Administration of B7. 2Ig fusion protein significantly enhanced T helper cell and CTL responses. These findings suggest that soluble forms of human B7.2 protein may provide a straightforward and practical method of supplying optimal costimulation during clinical immunotherapy. Copyright 1999 Academic Press.
机译：T细胞识别的I类和II类限制性肿瘤相关肽的鉴定已导致测试这些肽作为癌症患者实验免疫疗法中的免疫原。然而，最佳的T细胞活化需要通过抗原的T细胞受体和共刺激途径进行信号传递。 B7.1和B7.2是在抗原呈递细胞表面表达的强大的共刺激分子。使用小鼠模型，我们试图通过在肽免疫时施用可溶性形式的B7.2来优化抗肽反应期间的共刺激信号。 B7的管理。 2Ig融合蛋白显着增强T辅助细胞和CTL反应。这些发现表明，人B7.2蛋白的可溶形式可能提供一种在临床免疫疗法中提供最佳协同刺激作用的简单实用方法。版权所有1999，学术出版社。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号